Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HOTH Hoth Therapeutics	$1.13 -3.4%	$1.02	$0.58 ▼ $3.80	$14.93M	0.55	3.72 million shs	429,679 shs
NERV Minerva Neurosciences	$1.78 -1.1%	$1.68	$1.15 ▼ $3.50	$12.45M	-0.37	22,929 shs	10,525 shs
ONVO Organovo		$3.94	$1.56 ▼ $21.96	$3.47M	1.13	617,505 shs	243,634 shs
RLYB Rallybio	$0.33 -8.2%	$0.32	$0.22 ▼ $1.54	$13.84M	-1.24	109,466 shs	129,762 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HOTH Hoth Therapeutics	0.00%	-6.61%	+30.29%	+9.71%	+22.83%
NERV Minerva Neurosciences	0.00%	-0.84%	+18.67%	-1.66%	-43.49%
ONVO Organovo	0.00%	0.00%	0.00%	-15.35%	-77.56%
RLYB Rallybio	0.00%	+8.52%	+4.26%	-48.04%	-76.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HOTH Hoth Therapeutics	2.0112 of 5 stars	3.6	2.0	0.0	0.0	2.4	0.0	0.6
NERV Minerva Neurosciences	4.1213 of 5 stars	3.0	4.0	0.0	4.6	2.2	0.0	1.3
ONVO Organovo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	2.739 of 5 stars	3.0	3.0	0.0	0.0	2.7	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HOTH Hoth Therapeutics	3.25	Buy	$4.00	253.98% Upside
NERV Minerva Neurosciences	2.00	Hold	$5.00	180.90% Upside
ONVO Organovo	0.00	N/A	N/A	N/A
RLYB Rallybio	2.00	Hold	$10.00	2,906.61% Upside

Current Analyst Ratings Breakdown

Latest ONVO, RLYB, NERV, and HOTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
4/15/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/15/2025	RLYB Rallybio	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/13/2025	RLYB Rallybio	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/9/2025	RLYB Rallybio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
4/8/2025	RLYB Rallybio	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/31/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.86 per share	N/A
NERV Minerva Neurosciences	N/A	N/A	$0.21 per share	8.52	($3.67) per share	N/A
ONVO Organovo	$122K	0.00	N/A	N/A	$0.02 per share	0.00
RLYB Rallybio	$640K	21.62	N/A	N/A	$1.49 per share	0.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HOTH Hoth Therapeutics	-$8.19M	-$1.14	N/A	N/A	N/A	N/A	-109.18%	-100.22%	8/8/2025 (Estimated)
NERV Minerva Neurosciences	$1.44M	$0.82	2.17	N/A	N/A	N/A	-20.68%	15.73%	8/5/2025 (Estimated)
ONVO Organovo	-$14.67M	-$10.20	N/A	N/A	N/A	-10,151.64%	-346.26%	-187.53%	N/A
RLYB Rallybio	-$57.78M	-$1.09	N/A	N/A	N/A	-5,682.19%	-72.31%	-64.78%	8/14/2025 (Estimated)

Latest ONVO, RLYB, NERV, and HOTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	NERV Minerva Neurosciences	-$1.07	-$0.50	+$0.57	-$0.50	N/A	N/A
5/12/2025	Q1 2025	HOTH Hoth Therapeutics	-$0.34	-$0.27	+$0.07	-$0.27	N/A	N/A
5/8/2025	Q1 2025	RLYB Rallybio	-$0.21	-$0.21	N/A	-$0.21	N/A	$0.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
ONVO Organovo	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HOTH Hoth Therapeutics	N/A	15.09	15.08
NERV Minerva Neurosciences	N/A	9.21	9.21
ONVO Organovo	N/A	0.72	1.72
RLYB Rallybio	N/A	14.68	14.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HOTH Hoth Therapeutics	7.08%
NERV Minerva Neurosciences	34.56%
ONVO Organovo	8.23%
RLYB Rallybio	90.34%

Insider Ownership

Company	Insider Ownership
HOTH Hoth Therapeutics	6.92%
NERV Minerva Neurosciences	8.60%
ONVO Organovo	3.72%
RLYB Rallybio	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HOTH Hoth Therapeutics	4	13.21 million	12.30 million	Not Optionable
NERV Minerva Neurosciences	9	6.99 million	6.39 million	Not Optionable
ONVO Organovo	20	1.70 million	14.79 million	Optionable
RLYB Rallybio	40	41.61 million	37.99 million	Not Optionable

ONVO, RLYB, NERV, and HOTH Headlines

Recent News About These Companies

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

June 13, 2025 | finance.yahoo.com

Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook

May 24, 2025 | investing.com

Rallybio shareholders elect directors, ratify auditor

May 18, 2025 | uk.investing.com

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 9, 2025 | finance.yahoo.com

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

April 29, 2025 | finance.yahoo.com

Jones Trading Downgrades Rallybio (RLYB)

April 15, 2025 | msn.com

Rallybio downgraded to Hold from Buy at JonesResearch

April 14, 2025 | markets.businessinsider.com

Rallybio downgraded to In Line from Outperform at Evercore ISI

April 11, 2025 | markets.businessinsider.com

Rallybio (RLYB) was downgraded to a Hold Rating at H.C. Wainwright

April 10, 2025 | markets.businessinsider.com

Rallybio Stock Short Interest Report | NASDAQ:RLYB | Benzinga

April 9, 2025 | benzinga.com

Rallybio discontinues RLYB212 program

April 9, 2025 | markets.businessinsider.com

Rallybio sinks as it drops RLYB212 for prevention of FNAIT

April 9, 2025 | thepharmaletter.comT

HC Wainwright & Co. Downgrades Rallybio (RLYB)

April 9, 2025 | msn.com

RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks

April 9, 2025 | zacks.com

Citizens JMP downgrades Rallybio on RLYB212 discontinuation

April 9, 2025 | markets.businessinsider.com

JMP Securities downgrades Rallybio (RLYB) to a Hold

April 9, 2025 | theglobeandmail.com

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

April 8, 2025 | benzinga.com

Rallybio Discontinues Development of Treatment for Prevention of Rare Immune Disorder

April 8, 2025 | marketwatch.com

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

April 8, 2025 | finance.yahoo.com

Rallybio reports Q4 EPS (25c), consensus (30c)

March 13, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONVO, RLYB, NERV, and HOTH Company Descriptions

Hoth Therapeutics NASDAQ:HOTH

$1.13 -0.04 (-3.42%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.12 0.00 (-0.44%)

As of 06/27/2025 07:53 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Minerva Neurosciences NASDAQ:NERV

$1.78 -0.02 (-1.11%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.68 -0.10 (-5.62%)

As of 06/27/2025 04:19 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Organovo NASDAQ:ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

Rallybio NASDAQ:RLYB

$0.33 -0.03 (-8.25%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.34 +0.01 (+1.92%)

As of 06/27/2025 05:13 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time